Last reviewed · How we verify
Intravenous thrombolysis plus tirofiban
Intravenous thrombolysis plus tirofiban is a Fibrinolytic agent + Antiplatelet agent (combination therapy) Small molecule drug developed by The First Affiliated Hospital of University of Science and Technology of China. It is currently in Phase 3 development for Acute ischemic stroke, Acute myocardial infarction.
This combination uses intravenous thrombolysis to dissolve blood clots while tirofiban inhibits platelet aggregation to prevent clot reformation.
This combination uses intravenous thrombolysis to dissolve blood clots while tirofiban inhibits platelet aggregation to prevent clot reformation. Used for Acute ischemic stroke, Acute myocardial infarction.
At a glance
| Generic name | Intravenous thrombolysis plus tirofiban |
|---|---|
| Sponsor | The First Affiliated Hospital of University of Science and Technology of China |
| Drug class | Fibrinolytic agent + Antiplatelet agent (combination therapy) |
| Target | Fibrin (thrombolytic component); GPIIb/IIIa receptor (tirofiban component) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Intravenous thrombolysis (likely alteplase or similar fibrinolytic agent) breaks down existing thrombi by converting plasminogen to plasmin. Tirofiban is a glycoprotein IIb/IIIa inhibitor that blocks platelet aggregation by preventing fibrinogen binding to activated platelets. Together, they aim to restore blood flow while reducing thrombotic recurrence.
Approved indications
- Acute ischemic stroke
- Acute myocardial infarction
Common side effects
- Bleeding/hemorrhage
- Intracranial hemorrhage
- Thrombocytopenia
- Hypotension
Key clinical trials
- Prospective Registry of Endovascular Thrombectomy for eXtra-Large Ischemic Stroke
- Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke (NA)
- Intravenous Tirofiban Versus Alteplase Before Mechanical Thrombectomy in Stroke (PHASE2, PHASE3)
- Early Administration of Tirofiban in Patients Treated With Tenecteplase for Acute Ischemic Stroke (PHASE3)
- Intravenous Thrombolysis Combined With Tirofiban in Acute Ischemic Stroke (PHASE4)
- Advancing Stroke Safety and Efficacy Through Early Tirofiban Administration After Intravenous Thrombolysis (ASSET-IT) (PHASE3)
- Tirofiban for the Prevention of Early Neurological Deterioration After Intravenous Thrombolysis in Acute Ischemic Stroke (PHASE2, PHASE3)
- Patient Selection Using MR With Non-Perfusion Imaging for Endovascular Treatment Within 6 to 24 Hours (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous thrombolysis plus tirofiban CI brief — competitive landscape report
- Intravenous thrombolysis plus tirofiban updates RSS · CI watch RSS
- The First Affiliated Hospital of University of Science and Technology of China portfolio CI
Frequently asked questions about Intravenous thrombolysis plus tirofiban
What is Intravenous thrombolysis plus tirofiban?
How does Intravenous thrombolysis plus tirofiban work?
What is Intravenous thrombolysis plus tirofiban used for?
Who makes Intravenous thrombolysis plus tirofiban?
What drug class is Intravenous thrombolysis plus tirofiban in?
What development phase is Intravenous thrombolysis plus tirofiban in?
What are the side effects of Intravenous thrombolysis plus tirofiban?
What does Intravenous thrombolysis plus tirofiban target?
Related
- Drug class: All Fibrinolytic agent + Antiplatelet agent (combination therapy) drugs
- Target: All drugs targeting Fibrin (thrombolytic component); GPIIb/IIIa receptor (tirofiban component)
- Manufacturer: The First Affiliated Hospital of University of Science and Technology of China — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute ischemic stroke
- Indication: Drugs for Acute myocardial infarction
- Compare: Intravenous thrombolysis plus tirofiban vs similar drugs
- Pricing: Intravenous thrombolysis plus tirofiban cost, discount & access